Today, Lucerna announced the launch of the newest member in its fluorophore product line, OBI (3,5-difluoro-4-hydroxybenzylidene-imidazolinone-2-oxime-1-benzoimidazole). A derivative of BI, OBI exhibits enhanced stability to Red Broccoli™…
Lucerna will be presenting at the 3rd RNA-Targeted Drug Discovery Summit: December 8-10, 2020 Virtual Talk Presentation: “Spinach splice sensor: a cell-based drug discovery platform for…
On Thursday, May 28th, 2020, Lucerna will be giving a virtual talk to present the latest advances in its high-throughput RNA splicing drug discovery platform at the…
Lucerna is announcing the launch of a new R&D program to develop a new high-throughput screening (HTS) platform to enable the rapid discovery of drugs that…
Today, Lucerna announced the launch of the newest member in its fluorophore product line, DFHBI-BI or BI. A derivative of DFHBI, BI is the first photostable green…
Lucerna has received a 1 year $225K SBIR Phase I grant from the National Institute of Allergy and Infectious Diseases to develop new high-throughput screening (HTS)…
Lucerna has received a 2 year $1.5M SBIR Phase II contract from the National Cancer Institute to develop new R&D tools to enable scientists to better…
Lucerna will be presenting at SLAS 2020 International Conference & Exhibition: January 25-29, 2020 San Diego, CA Booth # 2029M Innovation AveNEW Ignite Award Presentation: Monday,…
Lucerna has been selected as a Innovate AveNew participant, a prestigious designation as one of the most promising emerging companies at the 2020 Society of Laboratory Automation…
Welcome to Lucerna’s new web page! Here we hope you will find information about our technology, team, and product offerings. Inside, we now have many beautiful illustrations…